Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Founded in 2001, our mission is to enhance the standard-of-care treatment for conditions associated with hypoxia, a potentially fatal shortage of oxygen in tissue and a serious complication of many of medicine’s most intractable and difficult-to-treat conditions. Our lead product candidate, Trans sodium crocetinate (TSC), is a first-in-class, small molecule therapeutic with a novel mechanism-of The company is applying its technology and its deep understanding of hypoxia to develop an intervention that may help save the lives of thousands of patients suffering from COVID-19 and other serious conditions. Lead drug trans sodium crocetinate (TSC), a first-in-class small molecule, directly targets and relieves oxygen-deprivation in affected tissue by enhancing oxygen diffusion through the blood and into the cells. Because the approach facilitates the passage of existing oxygen, rather than relying on an additional oxygen supply, it avoids the toxic side-effects of oxygen oversupply. Please beware of scams from individuals, organizations and Internet sites claiming to represent Diffusion in recruitment activities. Learn More: https://www.diffusionpharma.com/recruitment-fraud/ Terms Of Use: https://bit.ly/3FV97uj